U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06811805) titled 'Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard(R) Therapy for Prevention CSA-AKI' on Jan. 22.
Brief Summary: The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours after cardiac surgery in patients at risk of developing Cardiac Surgery Associated AKI (CSA-AKI) compared to standard-of-care (SoC).
Participants will be randomized (1:1) to one of the two study groups. The Treatment study group will be managed with the RenalGuard System. The RenalGuard treatment will start after induction of anesthesiology and will run during sur...